ASCO 2018: highlights in HER2-positive metastatic breast cancer.

摘要: At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate future directions of drug development this field. Early phase with novel antibody-drug conjugates (ADCs) such as trastuzumab-deruxtecan and trastuzumab-duocarmazine suggest relevant clinical activity drugs pretreated patients; addition, ADCs may offer low HER2-expressing tumours well. ZW25, a bispecific HER2-directed antibody targeting extracellular domains 2 4, showed excellent tolerability considerable single-agent activity. A combination T‑DM1 tyrosine-kinase inhibitor neratinib yielded high response rates, while a study trastuzumab plus durvalumab reported disappointing results. Although formally negative, overall survival PHEREXA trial dual HER2-inhibition pertuzumab patients prior treatment for advanced disease. A combined analysis two tucatinib that systemic therapy is active when continued case isolated central nervous system progression stable extracranial disease after local brain metastases; finally, a small prospective observation asymptomatic reduced left ventricular ejection fraction suggests anti-HER2 be reasonably safe population.